Alex Goldberg

OTC Active Stock Watch List: Provectus Pharmaceuticals, Inc. (OTC:PVCT) and AVT, Inc. (OTC:AVTC) Added to Equity Profile Report's OTC Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 01/08/2014 -- Equity Profile Report expands its OTC Active Stock Watch List adding Provectus Pharmaceuticals, Inc. (OTC:PVCT) and AVT, Inc. (OTC:AVTC).

Provectus Pharmaceuticals, Inc. (OTC:PVCT) a development-stage pharmaceutical company that engages in developing pharmaceuticals for oncology and dermatology indications is currently down (-0.43%) on 295,837 shares traded. Provectus Pharmaceuticals, Inc. (OTC:PVCT) is currently down (-22.67%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their OTC Active Stock Watch List.

Click Here to find out what other Investors are saying about Provectus Pharmaceuticals, Inc. (OTC:PVCT)

AVT, Inc. (OTC:AVTC) a company that develops, manufactures, and operates technology based product dispensing solutions and equipment is currently up (+20.00%) on 1,551,673 shares traded. AVT, Inc. (OTC:AVTC) is currently up (+607.96%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their OTC Active Stock Watch List.

Click Here to find out what other Investors are saying about AVT, Inc. (OTC:AVTC)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com